Drug Warning: Strattera
Generic name: atomoxetine HCI
Manufactured and marketed by: Eli Lilly & Co.
Purpose: Used in the treatment of attention deficit hyperactivity disorder, commonly referred to as ADHD, in both children and adults.
Side Effects Reported
- The more common side effects of Strattera may include nausea, decreased appetite, problems sleeping, mood swings, constipation, and sexual side effects.
- The side effects for children and adults may vary to some degree. Since Strattera is not a stimulant, there does not exist the same potential for substance abuse as there is with some of the alternative ADHD treatments like Adderall; however Strattera may be linked to some harmful side effects.
- Some patients who are prescribed Strattera may experience weight loss, impaired motor skills, increased blood pressure or heart rate, liver damage, and increased suicidal thoughts or actions.
Industry Report
In 2004, the FDA updated the labeling for Strattera with a new warning concerning the risk of severe liver damage. Two patients, one child and one adult, whom had both been taking Strattera for several months, developed liver injuries.
Similar to some popular antidepressants on the market, a black box warning has recently been added to Strattera concerning the risk of increased suicidal thoughts or actions amongst children who take the drug. The black box warning is the strongest warning the FDA has available to it.
Seeger Weiss is not currently pursuing lawsuits on this drug, but its drug warnings will remain on our radar.
- Asbestos
- Class Actions
- Commercial Litigation
- Defective Products
- Drug Injury
- Personal Injury
- Securities Fraud
- Toxic Exposure
- Accutane Side Effects
- Darvon and Darvocet
- DePuy Hip Recall
- Fosamax Femur Fractures
- Muscle Injury
- SSRI Birth Defects
- Topamax Birth Defects
- Transvaginal Surgical Mesh and Bladder Slings
- Tylenol Liver Damage
- Zocor/Simvastatin
